Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery

Clinical trial NCT05973864 · RECRUITING

Trial details

NCT number: NCT05973864
Sponsor: UNICANCER
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Triple Negative Breast Neoplasms

Start date: 2025-03-11
Primary completion: 2028-08-01
Enrollment: 220

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.